Hepatotoxicity of chemotherapy.
The selection of an antineoplastic regimen for an oncology patient is based first on the availability of effective drugs and then on a balancing of potential treatment-related toxicities with the patient's clinical condition and associated comorbidities. Liver function abnormalities are commonly observed in this patient population and identifying their etiology is often difficult. Immunosuppression, paraneoplastic phenomena, infectious diseases, metastases, and poly-pharmacy may cloud the picture. While criteria for standardizing liver injury have been established, dose modifications often rely on empiric clinical judgment. Therefore, a comprehensive understanding of hepatotoxic manifestations for the most common chemotherapeutic agents is essential. We herein review the hepatotoxicity of commonly used antineoplastic agents and regimens.
Division of Hematology and Medical Oncology, Department of Internal Medicine, University of Missouri-Columbia/Ellis Fischel Cancer Center, Columbia, MO 65203, USA.
Justin
J
Floyd
Irfan
I
Mirza
Bradley
B
Sachs
Michael C
MC
Perry
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury; D002986:Clinical Trials as Topic; D006801:Humans; D008099:Liver / Q000187:drug effects*; D009369:Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents